Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Congressional Leaders To Consider “Emergency Legislation” In Wake Of Heparin Safety Scare

This article was originally published in PharmAsia News

Executive Summary

Congressional leaders have ratcheted up the heat on U.S. FDA and Baxter Healthcare over their handling of the heparin safety scare, alleging that the agency has abandoned its policy to conduct preapproval inspections of API suppliers and saying they would consider introducing "emergency legislation" to mandate such inspections

You may also be interested in...



FDA Supply Chain Initiative And Foreign Inspection Increases Funded Under White House ’10 Budget

The $3.2 billion U.S. FDA budget proposed May 7 by the Obama administration includes a number of proposals aimed at ensuring global drug safety, including a $166 million initiative for improving supply chain safety for medical products

FDA Supply Chain Initiative And Foreign Inspection Increases Funded Under White House ’10 Budget

The $3.2 billion U.S. FDA budget proposed May 7 by the Obama administration includes a number of proposals aimed at ensuring global drug safety, including a $166 million initiative for improving supply chain safety for medical products

HHS Secretary Leavitt Calls For “Explicit Extraterritorial Jurisdiction” For U.S. FDA

U.S. Health and Human Services Secretary Michael Leavitt requested Congress in a Feb. 22 letter to grant FDA "explicit extraterritorial jurisdiction" to investigate manufacturers whose products are subject to the Federal Food, Drug, and Cosmetic Act

Related Content

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel